keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer neoadjuvant treatment

keyword
https://www.readbyqxmd.com/read/29786482/human-epidermal-growth-factor-2-positive-breast-cancer-with-mammographic-microcalcification-relationship-to-pathologic-complete-response-after-neoadjuvant-chemotherapy
#1
Fayyaz A K Mazari, Nisha Sharma, David Dodwell, Kieran Horgan
Purpose To determine the relationship between the presence or absence of mammographic calcifications in human epidermal growth factor receptor 2 (HER2)-positive breast cancers and pathologic complete response (pCR) to neoadjuvant chemotherapy and to determine other tumor and clinical characteristics that may be predictive of such a response. Materials and Methods A database of all patients with HER2-positive breast cancer who underwent neoadjuvant chemotherapy between 2007 and 2015 was retrospectively reviewed...
May 16, 2018: Radiology
https://www.readbyqxmd.com/read/29778821/evaluating-mastectomy-skin-flap-necrosis-in-the-extended-breast-reconstruction-risk-assessment-score-for-one-year-prediction-of-prosthetic-reconstruction-outcomes
#2
Nora Hansen, Sasa Espino, Jordan T Blough, Michael M Vu, Neil A Fine, John Ys Kim
BACKGROUND: Rates of mastectomy for breast cancer treatment and immediate reconstruction continue to rise. With increasing scrutiny on outcomes and patient satisfaction, there is an impetus for providers to be more deliberate in deciding appropriate patient selection for breast reconstruction. The Breast Reconstruction Risk Assessment (BRA) Score was developed for prediction of complications after primary prosthetic breast reconstruction, focusing on calculating risk estimations for a variety of complications based on individual patient demographics and perioperative characteristics...
May 17, 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29772459/tyrosine-kinase-inhibitors-for-brain-metastases-in-her2-positive-breast-cancer
#3
REVIEW
Renata Duchnowska, Sibylle Loibl, Jacek Jassem
Approximately 30-50% of advanced HER2-positive breast cancer patients will develop central nervous system (CNS) metastases, with an annual risk of around 10%, and a half of them will die from brain progression. An increased risk of brain metastases is also seen in patients with early HER2-positive breast cancer administered curative therapy. Brain metastases in HER2-positive breast cancer patients usually constitute the first site of recurrence. The administration of anti-HER2 monoclonal antibodies, trastuzumab and pertuzumab, considerably delays the onset of symptomatic brain disease: however, the limited penetration of these compounds into the CNS hinders their efficacy...
May 9, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29770955/laptm4b-gene-copy-number-gain-is-associated-with-inferior-response-to-anthracycline-based-chemotherapy-in-hormone-receptor-negative-breast-carcinomas
#4
Orsolya Rusz, Orsolya Papp, Laura Vízkeleti, Béla Ákos Molnár, Kristóf Csaba Bende, Gábor Lotz, Balázs Ács, Zsuzsanna Kahán, Tamás Székely, Ágnes Báthori, Csilla Szundi, Janina Kulka, Zoltán Szállási, Anna-Mária Tőkés
PURPOSE: To determine the associations between lysosomal-associated transmembrane protein 4b (LAPTM4B) gene copy number and response to different chemotherapy regimens in hormone receptor negative (HR-) primary breast carcinomas. PATIENTS AND METHODS: Two cohorts were analyzed: (1) 69 core biopsies from HR-breast carcinomas treated with neoadjuvant chemotherapy (anthracycline based in 72.5% of patients and non-anthracycline based in 27.5% of patients). (2) Tissue microarray (TMA) of 74 HR-breast carcinomas treated with adjuvant therapy (77...
May 16, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29770313/management-of-the-axilla-in-metaplastic-breast-carcinoma
#5
Brittany L Murphy, Robert T Fazzio, Tanya L Hoskin, Katrina N Glazebrook, Michael G Keeney, Elizabeth B Habermann, Tina J Hieken
Background: Metaplastic breast cancer (MBC), characterized by admixed epithelial, squamous or mesenchymal elements, constitutes <1% of breast cancers and has a poor prognosis but a paradoxically low reported rate of axillary lymph node (LN) involvement. Due to its rarity, data on appropriate axillary management is lacking, prompting this investigation of LN status and outcomes. Methods: We identified 41 MBC patients treated at our institution 2001-2011 who were followed for a median of 66 months...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29768500/clinically-relevant-inflammatory-breast-cancer-patient-derived-xenograft-derived-ex-vivo-model-for-evaluation-of-tumor-specific-therapies
#6
Bedrich L Eckhardt, Maria Gagliardi, LaKesla Iles, Kurt Evans, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Glauco Souza, Arvind Rao, Funda Meric-Bernstam, Naoto T Ueno, Geoffrey A Bartholomeusz
Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient survival. Like non-inflammatory breast cancer, IBC comprises multiple subtypes, with the triple-negative subtype being overrepresented. Although the current multimodality treatment regime of anthracycline- and taxane-based neoadjuvant therapy, surgery, and radiotherapy has improved the outcome of patients with triple-negative IBC, overall survival continues to be worse than in patients with non-inflammatory locally advanced breast cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29768327/survival-benefit-of-neoadjuvant-chemotherapy-for-resectable-breast-cancer-a-meta-analysis
#7
Yan Chen, Xiu-E Shi, Jin-Hui Tian, Xu-Juan Yang, Yong-Feng Wang, Ke-Hu Yang
BACKGROUND: Neoadjuvant chemotherapy (NAC) increases breast conservation rates in patients with resectable breast cancer at the associated cost of higher locoregional recurrence rates; however, the magnitude of the survival benefits of NAC for these patients remains undefined. Therefore, we aimed to clarify the survival benefit of NAC versus postoperative chemotherapy by conducting an updated meta-analysis of randomized clinical trials (RCTs). METHODS: The authors searched the Cochrane Library, PubMed, Embase, Web of Science, Chinese biomedical literature database, and Chinese Scientific Journals full-text database from their inception to December 2016...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29766686/multimodal-approach-in-assessment-of-the-response-of-breast-cancer-to-neoadjuvant-chemotherapy
#8
Mikhail Viktorovich Pavlov, Tatyana Igorevna Kalganova, Yekaterina Sergeevna Lyubimtseva, Vladimir Ivanovich Plekhanov, German Yurievich Golubyatnikov, Olga Yevgenyevna Ilyinskaya, Anna Gennadjevna Orlova, Pavel Vladimirovich Subochev, Dmitriy Vladimirovich Safonov, Natalia Mikhailovna Shakhova, Anna Vladimirovna Maslennikova
The ability for noninvasive visualization of functional changes of a tumor's oxygenation and circulatory system offers new advantages for prognosis and monitoring of the treatment efficacy. The results of breast cancer oxygen state study under chemotherapy action obtained by diffuse optical spectroscopy (DOS) in combination with Doppler ultrasonic imaging are presented. Complex use of optical and ultrasound methods gives complementary information about the size of the tumor node, peculiarities of its vascular bed, rate of its blood flow as well as oxygenation, and provide a picture of the tumor response to treatment...
May 2018: Journal of Biomedical Optics
https://www.readbyqxmd.com/read/29766409/where-youth-matters-clinicopathologic-characteristics-and-emerging-trends-in-treatment-and-outcomes-in-young-irish-women-with-breast-cancer
#9
Megan Greally, Jennifer Kielty, Geoffrey A Watson, Geoffrey Das, Christina Malouf, Lynda McSorley, Niamh Coleman, Cecily Quinn, Enda W McDermott, Giuseppe Gullo, John Crown, Ruth S Prichard, Catherine M Kelly, Janice M Walshe
BACKGROUND: Young women with breast cancer (YWBC) represent 7-12% of breast cancer diagnoses and ostensibly have more biologically aggressive subtypes with higher relapse and mortality rates. We studied the clinical and pathological characteristics in YWBC and examined how outcomes and treatment have evolved. METHODS: YWBC were identified from pathology databases at two tertiary centers. Patients were divided into two cohorts: those diagnosed from 2000 to 2005 (C1) and from 2006 to 2015 (C2)...
May 15, 2018: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/29758926/plasma-ccl5-promotes-emt-medicated-epirubicin-resistance-in-locally-advanced-breast-cancer
#10
Ge Ma, Huaxing Huang, Minghui Li, Li Li, Peng Kong, Yichao Zhu, Tiansong Xia, Shui Wang
Neoadjuvant chemotherapy (NCT) is the standard treatment for locally advanced breast cancer (LABC). Pathological complete response (pCR) is commonly used as a valid predictor of NCT long-term outcomes. Blood-based tumor biomarkers have the potential to predict response to NCT at early stage non-invasively. We believed plasma CCL5 could be a potential marker to predict NCT of LABC. Its efficiency and possible mechanism was studied in this work. Human Cytokine Antibody Microarray was applied to screen different cytokine concentration in plasma between low histological regression (Low-R) and high histological regression (High-R) patients...
May 4, 2018: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29758503/mri-and-pet-ct-for-evaluation-of-the-pathological-response-to-neoadjuvant-chemotherapy-in-breast-cancer-a-systematic-review-and-meta-analysis
#11
REVIEW
Huimin Li, Liang Yao, Penghui Jin, Lidong Hu, Xiaofei Li, Tiankang Guo, Kehu Yang
BACKGROUND: Neoadjuvant chemotherapy (NAC) has become an essential treatment for breast cancer. However, there is still no consensus on the best tool to evaluate pathological response to NAC. METHODS: Two reviewers systematically searched Cochrane, PubMed, EMBASE, Web of Science, and CBM (last updated in February 2017) for eligible articles. We independently screened and selected studies that conformed to the inclusion criteria and extracted the requisite data. Pooled sensitivity, specificity, and the area under the SROC curve were calculated to estimate the diagnostic accuracy of magnetic resonance imaging (MRI) and positron emission computed tomography (PET/CT)...
May 11, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29752333/the-endocrinology-of-male-breast-cancer
#12
REVIEW
Ian S Fentiman
Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E2 ) levels from hepatic conversion of androgen...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29750305/alterations-in-mrna-profiles-of-trastuzumab%C3%A2-resistant-her%C3%A2-2%C3%A2-positive-breast-cancer
#13
Bin Zhao, Yang Zhao, Yan Sun, Haitao Niu, Long Sheng, Dongfang Huang, Li Li
Breast cancer is one of the most common malignancies in women. Neoadjuvant trastuzumab therapy improves the prognosis of certain Her‑2‑positive breast cancer patients, however around two‑thirds of patients with Her‑2‑positive breast cancer do not benefit from Her‑2‑targeted therapy. To investigate the key mechanisms in trastuzumab resistance, potential biomarkers for neoadjuvant trastuzumab sensitivity were investigated using the gene expression omnibus (GEO) database for mRNA microarray data of Her‑2‑positive breast cancer patients who received neoadjuvant trastuzumab therapy...
May 7, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29747778/lymph-node-ratio-as-an-alternative-to-pn-staging-for-predicting-prognosis-after-neoadjuvant-chemotherapy-in-breast-cancer
#14
Dong Hui Cho, Soo Youn Bae, Ji Young You, Hong Kyu Kim, Young Woo Chang, Yoo Jin Choi, Sang Uk Woo, Gil Soo Son, Jae Bok Lee, Jeoung Won Bae, Seung Pil Jung
Axillary nodal status is one of the most important prognostic factors in breast cancer. The lymph node ratio (LNR) has been suggested as an independent prognostic factor because the number of dissected and involved lymph nodes might differ across institutions. Neoadjuvant chemotherapy (NAC) has been the preferred treatment method for reducing tumor mass in the breast and axillary area. However, NAC can reduce total number of excised lymph nodes compared with upfront surgery. Therefore, an emerging question is whether axillary nodal status and LNR following NAC can accurately predict prognosis...
June 2018: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/29745102/serbian-consensus-of-neoadjuvant-therapy-for-breast-cancer-neopulse
#15
Lazar Popovic, Zorica Tomasevic, Ljiljana Stamatovic, Ivan Markovic, Gorana Matovina-Brko, Marko Buta, Andrija Golubovic, Vladimir Selakovic, Jasna Trifunovic, Zafir Mutrezani, Nebojsa Ivanovic, Jasmina Nedovic, Srdjan Ninkovic, Sladjana Filipovic, Ana Cvetanovic, Nebojsa Djordjevic, Aleksandar Karanikolic, Tatjana Ivkovic-Kapic, Ferenc Vicko
Even though surgery is the primary treatment of operable breast cancer, it has been known for decades that the administration of postoperative adjuvant or preoperative neoadjuvant therapy is extremely important. Indications for neodjuvant therapy administration have been expanded over the years, and nowadays this kind of treatment represents an inevitable option in early breast cancer treatment. The NeoPULSE project, which gathered a group of experts in the field of breast cancer from five Serbian university centres, was formed with the aim to define optimal breast cancer diagnosis, indications for neoadjuvant therapy, therapeutic combinations in relation to molecular/biological parameters of breast cancer, as well as the treatment after neoadjuvant therapy...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29745080/multi-slice-spiral-ct-evaluation-of-breast-cancer-chemotherapy-and-correlation-between-ct-results-and-breast-cancerspecific-gene-1
#16
Jianlin Li, Wei Gao, Benxia Yu, Fuzheng Wang, Liping Wang
PURPOSE: To investigate multi-slice spiral CT (MSCT) imaging with breast cancer chemotherapy and the correlation between MSCT and breast cancer-specific gene 1 (BCSG1). METHODS: 86 patients with breast cancer were enrolled from January 2016 to May 2017. All of them were treated with neoadjuvant chemotherapy, and underwent MSCT scan before and after treatment to evaluate the efficacy of chemotherapy. The expression of BCSG1 in tumor tissue was detected by immunohistochemistry and the correlation between CT results and BCSG1 was analyzed...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29744672/efficacy-and-safety-of-neoadjuvant-treatment-with-bevacizumab-liposomal-doxorubicin-cyclophosphamide-and-paclitaxel-combination-in-locally-regionally-advanced-her2-negative-grade-iii-at-premenopausal-status-breast-cancer-a-phase-ii-study
#17
Ekaterini C Tampaki, Athanasios Tampakis, Constantinos E Alifieris, Dimitrios Krikelis, Anastasia Pazaiti, Michalis Kontos, Dimitrios T Trafalis
BACKGROUND: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. OBJECTIVE: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial growth factor (VEGF), bevacizumab plus chemotherapy combination of liposomal doxorubicin, cyclophosphamide and paclitaxel (PLAC-B). METHODS: Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma...
May 9, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29742918/can-unenhanced-mri-of-the-breast-replace-contrast-enhanced-mri-in-assessing-response-to-neoadjuvant-chemotherapy
#18
Beatrice Cavallo Marincola, Marianna Telesca, Fulvio Zaccagna, Frank Riemer, Michele Anzidei, Carlo Catalano, Federica Pediconi
Background The goals of neoadjuvant chemotherapy (NAC) are to reduce tumor volume and to offer a prognostic indicator in assessing treatment response. Contrast-enhanced magnetic resonance imaging (CE-MRI) is an established method for evaluating response to NAC in patients with breast cancer. Purpose To validate the role of unenhanced MRI (ue-MRI) compared to CE-MRI for assessing response to NAC in women with breast cancer. Material and Methods Seventy-one patients with ongoing NAC for breast cancer underwent MRI before, during, and at the end of NAC...
January 1, 2018: Acta Radiologica
https://www.readbyqxmd.com/read/29739815/impact-of-hormone-receptor-status-on-the-efficacy-of-her2-targeted-treatment
#19
Bin Zhao, Hong Zhao, Jiaxin Zhao
The introduction of human epidermal growth factor receptor 2 (HER2)-targeted drugs into routine clinical practice has a dramatic effect on the outlook for patients with HER2-positive breast cancer (BC). However, the association between efficacy of HER2-targeted therapy and hormone receptor (HR) status is still unclear. Here we conducted a meta-analysis of randomized controlled trials (RCTs) to address this issue in both neoadjuvant and adjuvant settings. PubMed and EMBASE were searched from inception to October 2017 for studies involving trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine and neratinib...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29734046/impact-of-neoadjuvant-chemotherapy-and-pathological-complete-response-on-eligibility-for-breast-conserving-surgery-in-patients-with-early-breast-cancer-a-meta-analysis
#20
Carmen Criscitiello, Mehra Golshan, William T Barry, Giulia Viale, Stephanie Wong, Michele Santangelo, Giuseppe Curigliano
PURPOSE: We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after neoadjuvant systemic therapy (NST) in patients with early breast cancer (EBC). PATIENTS AND METHODS: The primary outcome was breast-conserving surgery (BCT) rate. Secondary outcomes were pCR rate and association to BCT. Meta-analyses were performed using random effects models that use inverse-variance weighting for each treatment arm based on evaluable patients...
May 4, 2018: European Journal of Cancer
keyword
keyword
105931
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"